ClinicalTrials.gg
CompletedNCT04055623Tregs in ALSUpdated Oct 28, 2026Results posted

T-regulatory Cells in ALS

A Phase 2 interventional study of Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections and Monthly placebo infusions + 3 times per week placebo injections in ALS (Amyotrophic Lateral Sclerosis), sponsored by The Methodist Hospital Research Institute. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by The Methodist Hospital Research Institute · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
244th of 307
11 · median 33
Started
2019
with 19 others
Phase 2
89 of 440
8 open now
Registered
246th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 244th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2019, is one of 89 in phase 2, and was the 246th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same person whose Treg were removed, given back by IV (intravenously) and in combination with low-dose IL-2 in people with Amyotrophic Lateral Sclerosis (ALS).

Read the detailed description

Based on data collected in a previous study with a small group of patients, evidence was found to show that interfering with the immune system using Treg cells slowed ALS disease progression. It is known that Treg cell numbers and function are reduced in patients with ALS and in some patients with lower Treg cells, they have a more marked rapid progression of their ALS. For this study, there are two sites (in Houston, Texas and Boston, Massachusetts) in which Tregs will be taken from participants, increased or expanded outside the body, and then re-administered back to the participants from which the Tregs came.

This study has two parts and due to the pandemic two groups [Group 1 and Group 2]:

  1. The first period is a 6-month, randomized, placebo-controlled part of the study to study the biological activity, safety, and tolerability of the monthly expanded Tregs administered intravenously (IV) OR placebo (saline) administered intravenously plus subcutaneous low-dose Interleukin-2 (IL-2) OR subcutaneous placebo (saline) injections in 12 adults with ALS. IL2 helps regulate the immune system's white blood cells. [Group 1 only.]
  2. The second period is a 6-month OPEN-LABEL part of the study (no placebo) in which all participants will receive their own expanded Treg cells administered intravenously in combination with subcutaneous low-dose IL-2 at the following schedule: single dose of Treg cells twice (once per month with three IL2 injections per week); followed by double the dose of Treg cells twice (once per month with three IL2 injections per week); followed by triple the dose of Treg cells twice (one per month with three IL2 injection per week); followed by a 1 month follow-up safety visit after the last triple dose of Tregs with was received and the last set of IL2 injections three times per week injections. [Group 1 and Group 2.]

Groups:

GROUP 1 will go through the double-blind part of the study (receive either Tregs infusions and IL2 injections OR saline infusions and saline injections) for six months and open label part of the study (receive Treg injections and IL2 injections) for six months.

GROUP 2 will receive only the open label (Tregs infusions and IL2 injections) for six months.

This study is studying whether the enhancement of Treg numbers and function will slow disease progression.

In the first study of Tregs, we completed a single-center, open-label phase I study of Tregs from people with ALS. Tregs were increased outside the body and returned back to the individual Treg owners in multiple doses every 2 to 4 weeks. This early study provided evidence in a small group of patients that treatment with autologous Tregs may be effective in slowing ALS progression.

03

Conditions studied

  • ALS (Amyotrophic Lateral Sclerosis)

Keywords

  • Lou Gehrig's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ALS meeting El Escorial criteria for possible, probable, lab-supported probable, or definite ALS.
  • At least 18 years old.
  • Provided and authorized use of protected health information (PHI) in accordance with national and local patient privacy regulations.
  • Capable of complying with all study procedures, including the study drug delivery procedure, in the Investigator's opinion.
  • On a stable regimen of riluzole for at least 30 days at the time of screening. If not on riluzole at the time of study entry, willing to refrain from initiation of the agent for the duration of the trial.
  • Patients on edaravone willing to refrain from taking edaravone on the same day as they will receive the Tregs infusion for the duration of the trial. If not on edaravone at the time of study entry, willing to refrain from initiation of the agent for the duration of the trial.
  • Medical record documentation of a decline in ALSFRS-R total score of at least two points in the 90 days prior to screening or at least four points over the 180 days prior to screening.
  • Forced vital capacity (FVC) ≥65% of predicted capacity for age, height, and gender at screening.
  • Patient able and willing to undergo leukapheresis.

Exclusion criteria

Exclusion Criteria:

  • Presence of any of the following clinical conditions that would interfere with the safe conduct of the study, as determined by the Investigator:

    • Unstable neurological, cardiovascular, cerebrovascular, pulmonary, renal, hepatic, endocrine, or hematologic disease; active or infectious disease; or other medical illness.
    • Unstable psychiatric illness defined as psychosis (hallucinations or delusions), unstable major depression or substance abuse within 180 days prior to screening.
    • Persistent asthma, prior history of acute systemic reactions involving immunoglobulin E (IgE)-dependent mechanisms, history of angioedema, or history of anaphylactic reactions to any medication.
  • Serum (ALT) or aspartate aminotransferase (AST) greater than 3 times the (ULN) at screening.
  • Serum creatinine greater than 1.8 mg/dL or less than 40 mL/min at screening.
  • History of or positive test result for (HIV), virus, or virus (i.e., positive for both hepatitis B surface antigen and hepatitis B core antibody) at screening.
  • Tracheostomy.
  • If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or unwilling to use effective for the duration of the trial and for 90 days after treatment.
  • If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 90 days after treatment.
  • Enrollment in any other interventional study.
  • Treatment with another drug, biological agent, or device within 30 days or 5 half-lives of screening, whichever is longer. Patient participation in an observational/non-interventional clinical study is to be discussed with the Medical Monitor.
  • Prior gene or cell therapy treatments for ALS.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Intravenous infusion of Treg cells + Interleukin-2 injections

    For the first six months: T-regulatory cells taken from a participant will be increased in numbers outside the body in a lab and then returned back to the same participant through intravenous (IV) infusions once per month. The participant will also take Interleukin-2 (IL2) injections three times per week.

    Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections

  • Placebo comparator
    Intravenous infusion w/Placebo + matching placebo injections

    For the first six months: Participants will receive matching placebo or inactive intravenous (IV) infusions once per month. The participant will also take a matching inactive placebo injection three times per week.

    Other: Monthly placebo infusions + 3 times per week placebo injections

  • Experimental
    2nd 6-months Open Label: Treg Infusions + IL-2 injections

    For second six months: All participants will receive their own expanded/increased in numbers Treg cells by monthly infusion plus 3 times per week subcutaneous injections of IL-2.

    Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections

Interventions

  • BiologicalMonthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections

    For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections

    Also known as: Individualized therapy Treg cell infusions + Interleukin-2 (IL-2), Proleukin is brand name for IL-2

  • OtherMonthly placebo infusions + 3 times per week placebo injections

    For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections

    Also known as: inactive drug

  • BiologicalMonthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections

    For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.

    Also known as: Individualized therapy Treg cell infusions + Interleukin-2 (IL-2), Proleukin is the brand name for IL-2

06

What researchers measure

Primary outcomes

  1. Change in Treg Suppressive Function in the Blood From Baseline to Week 24.

    Change in Treg suppressive function on the proliferation of T-effector cells, as measured in percentage at baseline compared to week 24. Cohort 1-participants randomized to Tregs and IL-2 or matching placebos (no Tregs and saline. Cohort 2-participants from Cohort 1 who completed 6 Treg or placebo infusions and weekly IL-2 or placebo infusions plus 2 participants who went straight into Cohort 2 - Tregs and IL-2 (no placebo).

    Time frame: Baseline and week 24.

Secondary outcomes

  1. Change in Treg Numbers in the Blood From Baseline to Week 24.

    Change in Treg numbers in the blood at baseline compared to week 24; measured in % of total CD4+ cells.

    Time frame: Baseline and week 24

  2. Tolerability of Treg Infusions for 6 Months of Treatment

    Defined as the percentage of participants who complete the 6-month RCT.

    Time frame: Baseline to week 24.

  3. Tolerability of Ascending Doses of Tregs for 6 Months of Treatment

    Defined as the percentage of participants who complete the ascending doses of Tregs.

    Time frame: Baseline to week 24.

07

Results

Posted Oct 28, 2026
Limitations and caveats
Due to the COVID-19 pandemic, which affected travel, trial activities, staffing, and financing of the project, the planned 12 participants could not be enrolled. Two participants were unable to participate due to their Tregs not expanding in the lab.

Participant flow

Enrollment occurred from 08/14/2019 to 04/03/2020 at two academic ALS centers. Seven participants entered Period 1 (RCT): 4 placebo and 3 Treg/IL-2. Six completed the RCT and continued into Period 2 (OLE): 3 placebo and 3 Treg/IL-2; 1 placebo participant discontinued after a serious adverse event. Due to COVID-19-related impacts, 2 additional participants entered directly into the OLE, for 8 total OLE participants.

Period 1: RCT - Cohort 1
Participant flow — Period 1: RCT - Cohort 1
MilestoneCohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections
Started340
Continued to ole330
Completed330
Not completed010
Withdrew: Adverse event010
Period 2: OLE - Cohorts 1 and 2
Participant flow — Period 2: OLE - Cohorts 1 and 2
MilestoneCohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections
Started008
Completed008
Not completed000

Outcome measures

PrimaryChange in Treg Suppressive Function in the Blood From Baseline to Week 24.

Change in Treg suppressive function on the proliferation of T-effector cells, as measured in percentage at baseline compared to week 24. Cohort 1-participants randomized to Tregs and IL-2 or matching placebos (no Tregs and saline. Cohort 2-participants from Cohort 1 who completed 6 Treg or placebo infusions and weekly IL-2 or placebo infusions plus 2 participants who went straight into Cohort 2 - Tregs and IL-2 (no placebo).

Time frame:
Baseline and week 24.
Reported as:
Mean · percentage of Treg suppressive function
Change in Treg Suppressive Function in the Blood From Baseline to Week 24.
percentage of Treg suppressive functionCohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections
Change in Treg Suppressive Function in the Blood From Baseline to Week 24.30.2 ± 15.826.3 ± 18.328.0 ± 15.9
SecondaryChange in Treg Numbers in the Blood From Baseline to Week 24.

Change in Treg numbers in the blood at baseline compared to week 24; measured in % of total CD4+ cells.

Time frame:
Baseline and week 24
Reported as:
Mean · percentage of total CD4+ cells
Change in Treg Numbers in the Blood From Baseline to Week 24.
percentage of total CD4+ cellsCohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 6-months Open Label: Treg Infusions + IL-2 Injections
Change in Treg Numbers in the Blood From Baseline to Week 24.3.17 ± 0.554.45 ± 2.383.90 ± 1.84
SecondaryTolerability of Treg Infusions for 6 Months of Treatment

Defined as the percentage of participants who complete the 6-month RCT.

Time frame:
Baseline to week 24.
Reported as:
Count of participants · Participants
Tolerability of Treg Infusions for 6 Months of Treatment
ParticipantsCohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 6-months Open Label: Treg Infusions + IL-2 Injections
Tolerability of Treg Infusions for 6 Months of Treatment338
SecondaryTolerability of Ascending Doses of Tregs for 6 Months of Treatment

Defined as the percentage of participants who complete the ascending doses of Tregs.

Time frame:
Baseline to week 24.
Reported as:
Count of participants · Participants
Tolerability of Ascending Doses of Tregs for 6 Months of Treatment
ParticipantsCohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 6-months Open Label: Treg Infusions + IL-2 Injections
Tolerability of Ascending Doses of Tregs for 6 Months of Treatment338

Adverse events

Collected over Adverse Events were collected from the time the consent form was executed throughout the study, up to 15 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Infusion of Treg Cells + Interleukin-2 Injections0/3 (0%)0/3 (0%)0/3 (0%)
Intravenous Infusion w/Placebo + Matching Placebo Injections0/4 (0%)1/4 (25%)0/4 (0%)
2nd 6-months Open Label: Treg Infusions + IL-2 Injections0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent serious events
Most frequent serious events
EventIntravenous Infusion of Treg Cells + Interleukin-2 InjectionsIntravenous Infusion w/Placebo + Matching Placebo Injections2nd 6-months Open Label: Treg Infusions + IL-2 Injections
Anaphylaxis reaction to the 2nd double-blind infusionImmune system disorders0/31/40/8
Most frequent other events
Most frequent other events
EventIntravenous Infusion of Treg Cells + Interleukin-2 InjectionsIntravenous Infusion w/Placebo + Matching Placebo Injections2nd 6-months Open Label: Treg Infusions + IL-2 Injections
increased lacrimationEye disorders0/30/41/8

Baseline characteristics

11 Participants signed consent for the study, 9 were eligible for treatment. Six (6) participants who completed Cohort 1 are included in Cohort 2. Two (2) participants only participated in Cohort 2 only. One participant in Cohort 1 had 2 infusions, the second one was interrupted and stopped early due to an infusion reaction.

Age, Categorical
Age, Categorical(Participants)Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 InjectionsTotal
<=18 years0000
Between 18 and 65 years3418
>=65 years0011
Age, Continuous
Age, Continuous(years)Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 InjectionsTotal
Median46.2 ± 5.652.5 ± 6.849.7 ± 1149.8 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 InjectionsTotal
Female1012
Male2417
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 InjectionsTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White3429
More than one race0000
Unknown or Not Reported0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 InjectionsTotal
Hispanic or Latino0000
Not Hispanic or Latino3429
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(country)Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 InjectionsCohort 1: Intravenous Infusion w/Placebo + Matching Placebo InjectionsCohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 InjectionsTotal
United States3429
08

Study locations

2 sites
  • Massachusetts General Hospital Neurological Clinical Research Institute
    Boston, Massachusetts 02114, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 Apr;6(4):345-52. doi: 10.1038/ni1178. PubMed 15785760 ↗
  • Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004 Apr 5;199(7):971-9. doi: 10.1084/jem.20031579. PubMed 15067033 ↗
  • Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology. 2006 Mar;117(3):289-300. doi: 10.1111/j.1365-2567.2005.02317.x. PubMed 16476048 ↗
  • Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134. PubMed 26606968 ↗
  • Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011 May;134(Pt 5):1293-314. doi: 10.1093/brain/awr074. PubMed 21596768 ↗
  • Zhao W, Beers DR, Liao B, Henkel JS, Appel SH. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis. 2012 Dec;48(3):418-28. doi: 10.1016/j.nbd.2012.07.008. Epub 2012 Jul 17. PubMed 22820142 ↗
  • Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013 Jan;5(1):64-79. doi: 10.1002/emmm.201201544. Epub 2012 Nov 9. PubMed 23143995 ↗
  • Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, Thonhoff JR, Alsuliman AS, Shpall EJ, Rezvani K, Appel SH. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017 Mar 9;2(5):e89530. doi: 10.1172/jci.insight.89530. PubMed 28289705 ↗
  • Alsuliman A, Appel SH, Beers DR, Basar R, Shaim H, Kaur I, Zulovich J, Yvon E, Muftuoglu M, Imahashi N, Kondo K, Liu E, Shpall EJ, Rezvani K. A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Cytotherapy. 2016 Oct;18(10):1312-24. doi: 10.1016/j.jcyt.2016.06.012. Epub 2016 Aug 3. PubMed 27497700 ↗
  • Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018 May 18;5(4):e465. doi: 10.1212/NXI.0000000000000465. eCollection 2018 Jul. PubMed 29845093 ↗
  • Thonhoff JR, Berry JD, Macklin EA, Beers DR, Mendoza PA, Zhao W, Thome AD, Triolo F, Moon JJ, Paganoni S, Cudkowicz M, Appel SH. Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022 Aug 29;9(6):e200019. doi: 10.1212/NXI.0000000000200019. Print 2022 Nov. PubMed 36038262 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified data may be shared with requests directed to the research clinical investigators.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: At the end of the study via data management plan for duration of Treg studies.

Access criteria: Request to PI.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Aug 2021, 24 months.

Results were first posted in Oct 2026, 5 years 1 month after primary completion.

Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's 24 months is below that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion May 2022 → Aug 2021 and completion Aug 2022 → Sep 2021.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2019
First posted
Aug 14, 2019
StartActual
Aug 14, 2019
Primary completionActual
Aug 31, 2021was May 2022
CompletionActual
Sep 15, 2021was Aug 2022
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 28, 2026
Results
Results posted
posted Oct 28, 2026
Start date
Aug 7, 2019→Aug 14, 2019
Oct 28, 2026
Primary completion
May 31, 2022→Aug 31, 2021 (actual)
Oct 28, 2026
Study completion
Aug 31, 2022→Sep 15, 2021 (actual)
Oct 28, 2026
Enrollment
12 (estimated)→11 (actual)
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Treg suppressive functionSuppressive Function in the blood from baselineBlood From Baseline to weekWeek 24.Time frame: Baseline and week 24.
Oct 28, 2026
Documents
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedChange in Treg numbersNumbers in the blood from baselineBlood From Baseline to weekWeek 24.Time frame: Baseline and week 24
  • EditedTolerability of Treg infusionsInfusions for 6 monthsMonths of treatmentTreatmentTime frame: Baseline to week 24.
  • EditedTolerability of ascending dosesAscending Doses of Tregs for 6 monthsMonths of treatmentTreatmentTime frame: Baseline to week 24.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Status unknown→Completed
    Results posted
    Start date Aug 7, 2019→Aug 14, 2019
    Primary completion May 31, 2022→Aug 31, 2021 (now actual)
    Study completion Aug 31, 2022→Sep 15, 2021 (now actual)
    Enrollment 12 (estimated)→11 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Treg suppressive functionSuppressive Function in the blood from baselineBlood From Baseline to weekWeek 24.Time frame: Baseline and week 24.
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedChange in Treg numbersNumbers in the blood from baselineBlood From Baseline to weekWeek 24.Time frame: Baseline and week 24
    • EditedTolerability of Treg infusionsInfusions for 6 monthsMonths of treatmentTreatmentTime frame: Baseline to week 24.
    • EditedTolerability of ascending dosesAscending Doses of Tregs for 6 monthsMonths of treatmentTreatmentTime frame: Baseline to week 24.
    + 4 other changes: verification date, responsible party, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04055623
Collaborators
Massachusetts General Hospital, The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston, North East Amyotrophic Lateral Sclerosis Consortium
Responsible party
Sponsor
First posted
Aug 14, 2019
Start date
Aug 14, 2019
Primary completion
Aug 31, 2021
Completion
Sep 15, 2021
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Stanley H. Appel, MD
study director · The Methodist Hospital Research Institute
Jason R. Thonhoff, MD, PhD
principal investigator · The Methodist Hospital Research Institute
James D. Berry, MD, MPH
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion